Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Pousada, Guillermo ^a   Baloira, Adolfo ^b   Vilariño, Carlos ^c   Cifrian, Jose Manuel ^d   Valverde, Diana ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b Respiratory Division Complejo Hospitalario Universitario de Pontevedra   (Spain)

^c UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; POTASSIUM CHANNEL KV1.5; ACTIVIN RECEPTOR 2; ACVRL1 PROTEIN, HUMAN; BMPR2 PROTEIN, HUMAN; KCNA5 PROTEIN, HUMAN;

ACVRL1 GENE; ADULT; ARTICLE; BMPR2 GENE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE; GENE AMPLIFICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HEART INDEX; HEMODYNAMIC PARAMETERS; HETEROZYGOTE; HUMAN; KCNA5 GENE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; NON IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PULMONARY HYPERTENSION; TREADMILL TEST; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; HEMODYNAMICS; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; PROGNOSIS;

ACTIVIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; KV1.5 POTASSIUM CHANNEL; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PROGNOSIS;

EID: 84903178918     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100261     Document Type: Article

References (43)

1. Johnson JA, Vnencak-Jones CL, Cogan JD, Loyd JE, West J (2009) Copynumber variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension. Med Gen 10: 58-60.
2. Machado RD, Eickelberg O, Elliott G, Geraci MW, Hanaoka M, et al. (2009) Genetics and Genomics of Pulmonary Arterial Hypertension. J Am Coll Cardiol 54: 1, Suppl S.
3. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S (2007) An epidemiological study of pulmonary arterial hypertension. Eur Respir J 30: 104-109.
4. Ulrich S, Szamalek-Hoegel J, Hersberger M, Fischler M, Solera-García J, et al. (2010) Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease. Respiration 79: 279-287.
5. Sanchez O, Marié E, Lerolle U, Wermert D, Israël-Biel D, et al. (2010) Pulmonary arterial hypertension in women. Rev Mal Respir 27: e79-e87.
6. Austin ED, Phillips JA, Cogan JD, Hamid R, Yu C, et al. (2009) Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 10: 87-96.
7. Davies RJ, Morrell NW (2008) Molecular mechanisms of Pulmonary Arterial Hypertension: Morphogenetic protein type II receptor. Chest 134: 1271-1277.
8. Morrell NW (2010) Genetics of pulmonary arterial hypertension: do the molecular findings have translational value?. f1000 Biology Reports 2: 22-24.
9. O'Callaghan AS, Balada E, Serrano-Acedo S, Simeon-Aznar CP, Ordi-Ros J (2007) Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease. Clin Rheumatol 26: 947-949.
10. Upton PD, Davies RJ, Trembath RC, Morrell NW (2009) Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells. J Biol Chem 284: 15794-15804.
11. Garrido-Martin EM, Blanco FJ, Fernandez-L A, Langa C, Vary VP, et al. (2010) Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1. BMC Molecular Biology 11: 51-73.
12. Wipff J, Dieudé P, Guedj M, Ruiz B, Riemekasten G, et al. (2010) Association of a KCNA5 Gene Polymorphism With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension in the European Caucasian Population. Arthritis & Rheumatism 62: 3093-3100.
13. Burg ED, Remillard CV, Yuan JX (2008) Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br J Pharmacol 153: S99-S111.
14. Galié N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30: 2493-537.
15. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67: 737-44.
16. Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, et al. (2007) The Activin Receptor-Like Kinase 1 Gene: Genomic Structure and Mutations in Hereditary Hemorrhagic Telangiectasia Type 2. Am J Hum Genet 61: 60-67.
17. Yang T, Yang P, Roden DM, Darbar D (2010) A novel KCNA5 Mutation Implicates Tyrosine Kinase Signaling in Human Atrial Fibrillation. Heart Rhythm 7(9): 1246-1252.
18. Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet 7(7): 20.
19. Ferrer-Costa C, Orozco M, de la Cruz X (2004) Sequence-based prediction of pathological mutations. Proteins 57(4): 811-9.
20. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7): 1073-81.
21. Santos C, Peixoto A, Rocha P, Pinto P, Bizarro S, et al. (2014) Pathogenicity Evaluation of BRCA1 and BRCA2 Unclassified Variants Identified in Portuguese Breast/Ovarian Cancer Families. J Mol Diagn 16(3): 324-334.
22. Portillo K, Santos S, Madrigal I, Blanco I, Paré C, et al. (2010) Study of the BMPR2 gene in patients with pulmonary arterial hypertension. Arch Bronconeumol 46: 129-34.
23. Fessel JP, Loyd JE, Austin ED (2011) The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm Circ 1: 305-319.
24. Girerd B, Montani D, Eyries M, Yaici A, Sztrymf B, et al. (2010) Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 11: 73-80.
25. Pfarr N, Fischer C, Ehlken N, Becker-Grünig T, López- González V, et al. (2013) Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension. Respir Res 14: 3-12.
26. Elliot CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, et al. (2006) Relationship of BMPR2 mutations to vasoreactivity in Pulmonary Arterial Hypertension. Circulation 113: 2509-2515.
27. Hamid R, Cogan JD, Hedges LK, Austin E, Phillips III JA, et al. (2009) Penetrance of Pulmonary Arterial Hypertension is modulated by the expression of normal BMPR2 allele. Hum Mutat 30(4): 649-654.
28. Majka S, Hagen M, Blackwell T, Harral J, Johnson JA, et al. (2011) Physiologic and molecular consequences of endothelial BMPR2 mutation. Respir Res 12: 84-96.
29. Pfarr N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, et al. (2011) Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res 12: 99-109.
30. Chida A, Shintani M, Nakayama T, Furutani Y, Hayama E, et al. (2012) Missense Mutations of the BMPR1B (ALK6) Gene in Childhood Idiopathic Pulmonary Arterial Hypertension. Circ J 76(7): 1804-1811.
31. Machado RD, Aldred MA, James V, Harrison RE, Patel B, et al. (2006) Mutations of the TGF-b Type II Receptor BMPR2 in Pulmonary Arterial Hypertension. Hum Mutat 27(2): 121-132.
32. Czech A, Fedyunin I, Zhang G, Ignatova Z (2010) Silent mutations in sight: covariations in tRNA abundance as a key to unravel consequences of silent mutations. Mol BioSyst 6: 1767-1772.
33. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, et al. (2010) Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation. Am J Respir Crit Care Med 181: 851-861.
34. Selva-O'Callaghan A, Balada E, Serrano-Acedo S, Simeon-Aznar CP, Ordi-Ros J (2007) Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease. Clin Rheumatol 26: 947-949.
35. Fujiwara M, Yagi H, Matsuoka R, Akimoto K, Furutani M, et al. (2008) Implications of Mutations of Activin Receptor-Like Kinase 1 Gene (ALK1) in Addition to Bone Morphogenetic Protein Receptor II Gene (BMPR2) in Children With Pulmonary Arterial Hypertension. Circ J 72: 127-133.
36. Abdalla SA, Cymerman U, Johnson RM, Deber CM, Letarte M (2003) Disease-associated mutations in conserved residues of ALK-1 kinase domain. Eur J Hum Genet 11: 279-287.
37. Schulte C, Geisthoff U, Lux A, Kupkal S, Zenner HP, et al. (2005) High frequency of ENG and ALK1/ACVRL1 mutations in german HHT patients. Hum Mutat 25(6): 595-602.
38. Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, et al. (2007) Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292: C1837-C1853.
39. Christophersen IE, Olesen MS, Liang B, Andersen MN, Larsen AP, et al. (2013) Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation. Eur Heart J 34(20): 1517-25.
40. Burg ED, Platoshyn O, Tsigelny IF, Lozano-Ruiz B, Rana BK, et al. (2010) Tetramerization domain mutations in KCNA5 affect channel kinetics and cause abnormal trafficking patterns. Am J Physiol Cell Physiol 98(3): C496-509.
41. Kurata HT, Soon GS, Eldstrom JR, Lu GW, Steele DF, et al. (2002) Aminoterminal determinants of U-type inactivation of voltage-gated K+ channels. J Biol Chem 277(32): 29045-53.
42. + channels in pulmonary arterial smooth muscle cells. J. Smooth Muscle Res 46(2): 89-105.
43. Liu D, Wu WH, Mao YM, Yuan P, Zhang R, et al. (2012) BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. Circ Cardiovasc Genet 5(5): 511-8.